10 research outputs found
Neutralization, effector function and immune imprinting of Omicron variants
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on viral infection and transmission and the efficacy of vaccines and therapies remains poorly understood. Here we demonstrate that recently emerged BQ.1.1 and XBB.1.5 variants bind host ACE2 with high affinity and promote membrane fusion more efficiently than earlier Omicron variants. Structures of the BQ.1.1, XBB.1 and BN.1 RBDs bound to the fragment antigen-binding region of the S309 antibody (the parent antibody for sotrovimab) and human ACE2 explain the preservation of antibody binding through conformational selection, altered ACE2 recognition and immune evasion. We show that sotrovimab binds avidly to all Omicron variants, promotes Fc-dependent effector functions and protects mice challenged with BQ.1.1 and hamsters challenged with XBB.1.5. Vaccine-elicited human plasma antibodies cross-react with and trigger effector functions against current Omicron variants, despite a reduced neutralizing activity, suggesting a mechanism of protection against disease, exemplified by S309. Cross-reactive RBD-directed human memory B cells remained dominant even after two exposures to Omicron spikes, underscoring the role of persistent immune imprinting
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant–neutralizing antibody that is a strong candidate for clinical development
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity. While most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant antibody, that is unaffected by any Omicron lineage spike mutations and is a strong candidate for clinical development
Effects of pharmacological inhibition of Sigma-1 on Cancer Stem Cell biology
Prostate cancer (PCa) is the second most frequent cancer in men worldwide. The clinical evolution of PCa is quite heterogeneous, ranging from indolent to very aggressive tumors that rapidly evolve in metastatic and castration resistant prostate cancer (CRPC). The factors that contribute to the heterogeneity and aggressive clinical behavior of PCa are not clear. The conventional therapies have proved to be inefficient with a high probability of tumor relapse and evolution in more severe forms. One of the underlying causes is the existence of a subpopulation of cells with stem-like properties, termed cancer stem cells (CSCs). CSCs play a role as tumorinitiating and tumor propagating cells. They are capable of continuous self-renewal and are able to generate more differentiated non-stem cancer cells. One of their hallmarks is the reprogramming of the cellular energy metabolism. This feature provides to CSCs the ability to respond to metabolic stress, adapt and survive.
Understanding the mechanisms sustaining CSC metabolism may identify relevant targets for therapeutic applications. In this context, the chaperon protein Sigma-1 represents an interesting target for CSC-directed approaches. Sigma-1 is localized at the mitochondria endoplasmic reticulum interface and controls many cellular processes, including Ca2+exchange, mitochondrial function and stress response.
Although the relevance of Sigma-1 in other diseases is well established, the potential role of Sigma-1 in cancer biology is just emerging.
In this project, we aimed at investigating the role of Sigma-1 in prostate cancer cells with different stem-like phenotype and tumorigenic potential. An additional aim wasto produce recombinant Sigma-1 protein to study binding to small molecule ligands
and protein-protein interactions for future mechanistic studies and design novel selective Sigma-1 inhibitors.
To achieve the first goal, androgen-receptor negative DU145 prostate cancer cells were cultured as bulk tumor cells or under conditions that enriched for stem-like tumor cells. Interestingly, we found that, after treatment with specific Sigma-1 inhibitors, proliferation of bulk tumor cells was only slightly affected. On the contrary, the ability to form tumor-spheres, a specific property of CSCs, was strongly reduced.
In parallel, we found that mitochondrial respiration was impaired after treatment with Sigma-1 ligands in cells growing in CSC selective conditions. These results suggest that inhibition of Sigma-1 has a major impact in the maintenance and expansion of the CSC subpopulation, likely by affecting mitochondrial respiration and function. Sigma-1 appears as a promising target for CSC eradication and novel specific inhibitors might be effective anticancer drugs
The Anti-Inflammatory Effect of the β1-Adrenergic Receptor Antagonist Metoprolol on High Glucose Treated Human Microvascular Retinal Endothelial Cells
Hyperglycemia-induced impairment of the blood-retinal barrier represents the main pathological event in diabetic retinopathy that is elicited by a reduced cellular response to an accumulation of reactive oxygen species (ROS) and increased inflammation. The purpose of the study was to evaluate whether the selective β1-adrenoreceptor (β1-AR) antagonist metoprolol could modulate the inflammatory response to hyperglycemic conditions. For this purpose, human retinal endothelial cells (HREC) were treated with normal (5 mM) or high glucose (25 mM, HG) in the presence of metoprolol (10 μM), epinephrine (1 μM), or both compounds. Metoprolol prevented both the HG-induced reduction of cell viability (MTT assays) and the modulation of the angiogenic potential of HREC (tube formation assays) reducing the TNF-α, IL-1β, and VEGF mRNA levels (qRT-PCR). Moreover, metoprolol prevented the increase in phospho-ERK1/2, phospho-cPLA2, COX2, and protein levels (Western blot) as well as counteracting the translocation of ERK1/2 and cPLA2 (high-content screening). Metoprolol reduced ROS accumulation in HG-stimulated HREC by activating the anti-oxidative cellular response mediated by the Keap1/Nrf2/HO-1 pathway. In conclusion, metoprolol exerted a dual effect on HG-stimulated HREC, decreasing the activation of the pro-inflammatory ERK1/2/cPLA2/COX2 axis, and counteracting ROS accumulation by activating the Keap1/Nrf2/HO-1 pathway
Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer
Cancer stem cells (CSCs) contribute to disease progression and treatment failure in human cancers. The balance among self-renewal, differentiation, and senescence determines the expansion or progressive exhaustion of CSCs. Targeting these processes might lead to novel anticancer therapies. Here, we uncover a novel link between BRD4, mitochondrial dynamics, and self-renewal of prostate CSCs. Targeting BRD4 by genetic knockdown or chemical inhibitors blocked mitochondrial fission and caused CSC exhaustion and loss of tumorigenic capability. Depletion of CSCs occurred in multiple prostate cancer models, indicating a common vulnerability and dependency on mitochondrial dynamics. These effects depended on rewiring of the BRD4-driven transcription and repression of mitochondrial fission factor (Mff). Knockdown of Mff reproduced the effects of BRD4 inhibition, whereas ectopic Mff expression rescued prostate CSCs from exhaustion. This novel concept of targeting mitochondrial plasticity in CSCs through BRD4 inhibition provides a new paradigm for developing more effective treatment strategies for prostate cancer
Peripubertal cannabidiol treatment rescued behavioral and neurochemical abnormalities in the MAM model of schizophrenia
In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic
agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations
such as social withdrawal and cognitive impairment in the social interaction test and in the novel object
recognition test, respectively. At molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and
protein expression which might be due to a reduction in DNA methylation at gene promoter in the prefrontal
cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM
rats. Both schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed
by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol
(30mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251
(0.5mg/kg/day), but not with haloperidol (0.6mg/kg/day). These results suggest that early treatment with
cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC
at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult
Neutralization, effector function and immune imprinting of Omicron variants
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain 1 (RBD) of the spike protein. The effects of these mutations on viral infection and transmission and the efficacy of vaccines and therapies remains poorly understood. Here we demonstrate that recently emerged BQ.1.1 and XBB.1.5 variants bind host ACE2 with high affinity and promote membrane fusion more efficiently than earlier Omicron variants. Structures of the BQ.1.1, XBB.1 and BN.1 RBDs bound to the fragment antigen-binding region of the S309 antibody (the parent antibody for sotrovimab) and human ACE2 explain the preservation of antibody binding through conformational selection, altered ACE2 recognition and immune evasion. We show that sotrovimab binds avidly to all Omicron variants, promotes Fc-dependent effector functions and protects mice challenged with BQ.1.1 and hamsters challenged with XBB.1.5. Vaccine-elicited human plasma antibodies cross-react with and trigger effector functions against current Omicron variants, despite a reduced neutralizing activity, suggesting a mechanism of protection against disease, exemplified by S309. Cross-reactive RBD-directed human memory B cells remained dominant even after two exposures to Omicron spikes, underscoring the role of persistent immune imprinting
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
International audienceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma neutralizing activity against Omicron BA.1, BA.2, BA.2.12.1 and BA.4/5 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months post infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant neutralizing antibody, that is a strong candidate for clinical development